Crewe Advisors LLC Makes New Investment in Hims & Hers Health, Inc. (NYSE:HIMS)

Crewe Advisors LLC acquired a new position in shares of Hims & Hers Health, Inc. (NYSE:HIMS) during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 1,173 shares of the company’s stock, valued at approximately $28,000.

Other large investors have also recently bought and sold shares of the company. Raleigh Capital Management Inc. grew its stake in Hims & Hers Health by 1,100.0% during the fourth quarter. Raleigh Capital Management Inc. now owns 1,200 shares of the company’s stock worth $29,000 after buying an additional 1,100 shares in the last quarter. GAMMA Investing LLC lifted its holdings in shares of Hims & Hers Health by 2,173.7% in the fourth quarter. GAMMA Investing LLC now owns 2,251 shares of the company’s stock worth $54,000 after acquiring an additional 2,152 shares during the last quarter. Quest Partners LLC lifted its holdings in shares of Hims & Hers Health by 22.6% in the third quarter. Quest Partners LLC now owns 4,373 shares of the company’s stock worth $81,000 after acquiring an additional 807 shares during the last quarter. Nisa Investment Advisors LLC lifted its holdings in shares of Hims & Hers Health by 115.3% in the fourth quarter. Nisa Investment Advisors LLC now owns 4,560 shares of the company’s stock worth $110,000 after acquiring an additional 2,442 shares during the last quarter. Finally, Ausbil Investment Management Ltd bought a new position in shares of Hims & Hers Health in the fourth quarter worth about $127,000. 63.52% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Hims & Hers Health

In other Hims & Hers Health news, Director Anja Manuel purchased 4,000 shares of Hims & Hers Health stock in a transaction that occurred on Tuesday, November 12th. The stock was acquired at an average price of $26.94 per share, with a total value of $107,760.00. Following the transaction, the director now owns 4,000 shares in the company, valued at $107,760. This trade represents a ∞ increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Michael Chi sold 2,054 shares of Hims & Hers Health stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $33.56, for a total transaction of $68,932.24. Following the completion of the sale, the insider now directly owns 184,947 shares of the company’s stock, valued at approximately $6,206,821.32. The trade was a 1.10 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 1,167,913 shares of company stock valued at $34,303,787 in the last quarter. 17.71% of the stock is currently owned by company insiders.

Hims & Hers Health Stock Performance

NYSE:HIMS opened at $40.36 on Friday. The company has a market capitalization of $8.82 billion, a PE ratio of 91.72 and a beta of 1.35. The company has a 50 day simple moving average of $30.02 and a two-hundred day simple moving average of $23.12. Hims & Hers Health, Inc. has a fifty-two week low of $9.14 and a fifty-two week high of $44.43.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings data on Monday, November 4th. The company reported $0.32 EPS for the quarter, topping the consensus estimate of $0.06 by $0.26. The company had revenue of $401.56 million during the quarter, compared to the consensus estimate of $382.20 million. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The company’s quarterly revenue was up 77.1% on a year-over-year basis. During the same quarter last year, the firm posted ($0.04) EPS. Research analysts predict that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Wall Street Analysts Forecast Growth

HIMS has been the subject of a number of research reports. Needham & Company LLC increased their target price on shares of Hims & Hers Health from $28.00 to $31.00 and gave the stock a “buy” rating in a report on Monday, January 6th. Bank of America cut shares of Hims & Hers Health from a “buy” rating to an “underperform” rating and dropped their target price for the stock from $32.00 to $18.00 in a report on Thursday, November 14th. Morgan Stanley started coverage on shares of Hims & Hers Health in a report on Tuesday, December 17th. They issued an “overweight” rating and a $42.00 target price for the company. Citigroup lowered shares of Hims & Hers Health from a “neutral” rating to a “sell” rating and raised their price objective for the company from $24.00 to $25.00 in a report on Friday, January 10th. Finally, BTIG Research started coverage on shares of Hims & Hers Health in a report on Tuesday, January 7th. They issued a “buy” rating and a $35.00 price objective for the company. Two equities research analysts have rated the stock with a sell rating, seven have given a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat, Hims & Hers Health currently has a consensus rating of “Hold” and a consensus price target of $25.13.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.